Cargando…

Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial

AIMS: Pulmonary hypertension (PHT) may complicate heart failure with reduced ejection fraction (HFrEF) and is associated with a substantial symptom burden and poor prognosis. Sildenafil, a phosphodiesterase‐5 (PDE‐5) inhibitor, might have beneficial effects on pulmonary haemodynamics, cardiac functi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooper, Trond J., Cleland, John G.F., Guazzi, Marco, Pellicori, Pierpaolo, Ben Gal, Tuvia, Amir, Offer, Al‐Mohammad, Abdallah, Clark, Andrew L., McConnachie, Alex, Steine, Kjetil, Dickstein, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2022
Materias:	PULMONARY HYPERTENSION IN HFrEF
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544113/ https://www.ncbi.nlm.nih.gov/pubmed/35596935 http://dx.doi.org/10.1002/ejhf.2527

Ejemplares similares

The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta‐analysis of COMPANION and CARE‐HF
por: Cleland, John G.F., et al.
Publicado: (2022)

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
por: McDowell, Kirsty, et al.
Publicado: (2022)

Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial
por: Voors, Adriaan A., et al.
Publicado: (2020)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Current and future use of neuromodulation in heart failure( )
por: Duncker, David, et al.
Publicado: (2022)

Neuromodulation in heart failure( )
por: Zannad, Faiez
Publicado: (2022)

Neuromodulation devices for heart failure( )
por: Dusi, Veronica, et al.
Publicado: (2022)

Sympathetic activation in heart failure( )
por: Gronda, E, et al.
Publicado: (2022)

Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling
por: Taran, Irina N., et al.
Publicado: (2018)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension
por: Wronski, Samantha L., et al.
Publicado: (2019)

Pulmonary Hypertension in Heart Failure Patients
por: Rao, Sriram D, et al.
Publicado: (2020)

Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases?
por: Sobiecka, Małgorzata, et al.
Publicado: (2020)

Identifying Patients with Group 3 Pulmonary Hypertension Associated with COPD or ILD Using an Administrative Claims Database
por: Heresi, Gustavo A., et al.
Publicado: (2022)

Dear colleagues: enough with the men-only author panels
por: Van Spall, Harriette G C, et al.
Publicado: (2022)

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Time for change
por: Zieroth, Shelley, et al.
Publicado: (2022)

Representation matters: a call for inclusivity and equity in heart failure clinical trials
por: Reza, Nosheen, et al.
Publicado: (2022)

The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022)

A rationale for dedicated trials of combination therapy in heart failure
por: Blumer, Vanessa, et al.
Publicado: (2022)

Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022)

Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe
por: Marx, Nikolaus, et al.
Publicado: (2022)

Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come
por: Piña, Ileana L, et al.
Publicado: (2022)

Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology
por: Guazzi, Marco, et al.
Publicado: (2022)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Fukuta, Hidekatsu
Publicado: (2020)

What causes exertional dyspnoea in patients with atrial fibrillation? Implications for catheter ablation in patients with heart failure
por: Packer, Milton
Publicado: (2021)

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction
por: Chandramouli, Chanchal, et al.
Publicado: (2022)

Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study
por: Venkateshvaran, Ashwin, et al.
Publicado: (2022)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)
por: Linde, Cecilia, et al.
Publicado: (2022)

Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study
por: Chen, Shao-Liang, et al.
Publicado: (2015)

Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of Pulmonary Hypertension
por: Rothman, Alexander M.K., et al.
Publicado: (2015)

Epidemiology of pulmonary hypertension in the elderly
por: Örem, Cihan
Publicado: (2017)

How to select the appropriate candidate of pulmonary arterial hypertension: specific therapy in elderly patients with pulmonary hypertension
por: Yaylali, Yalin Tolga
Publicado: (2017)

Clinical and hemodynamic profiles of elderly patients with pulmonary arterial hypertension: a single center, prospective study
por: Ozpelit, Ebru, et al.
Publicado: (2017)

Which prognostic factors should be used in pulmonary arterial hypertension in elderly patients?
por: Akdeniz, Bahri, et al.
Publicado: (2017)

Mechanisms of ECG signs in chronic obstructive pulmonary disease
por: Larssen, Marte Strømsnes, et al.
Publicado: (2017)

The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg
por: Schrader, J, et al.
Publicado: (2009)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_j0h00ffakccghgkj7u1qan4ujs